Back to search

University of Ioannina

Η επίδραση της επιθετικής υπολιπιδαιμικής αγωγής σε αγγειακούς ασθενείς που υποβάλλονται σε χειρουργική θεραπεία

Abstract

dc:description

Objective: Cardiovascular and renal complications consist a major cause of morbidity and mortality in patients undergoing vascular surgery, compromising both short and long term prognosis. However little are known concerning the effect of intensified lipid lowering therapy on cardiovascular outcome and renal function in patients undergoing vascular surgery. This was a prospective randomized, open-label study to investigate the effect of lipid-lowering treatment by statin monotherapy or intensified by combining statin with ezetimibe on a 12-month prognosis after vascular surgery. Methods: Patients were randomly assigned to receive rosuvastatin (RSV) 10 mg/d or rosuvastatin 10 mg/d plus ezetemibe (RSV/EZT) 10 mg/d, starting prior to scheduled surgical procedure. The primary end point was the first major cardiovascular event, including death from cardiac causes, nonfatal myocardial infarction, ischemic stroke, and unstable angina. Renal function was assessed by measurements of serum creatinine concentration (sCr), estimated creatinine clearance (e-CrC) and urinary excretion of protein, creatinine and microalbumin. The measurements were performed preoperatively, postoperatively, at 1st, 6th and 12th month after the procedure.Results: A total of 136 patients assigned to RSV and 126 to RSV/EZT completed the study protocol. As many as 6.6% of patients in the RSV group experience a major cardiovascular event within 30 days after surgery versus 5.6% in the RSV/EZT group (p= 0.72). From month 1 to 12 of the follow-up period, primary end point was observed (9 taking RSV vs 2 in the RSV/EZT group [p=0.004]). Intensified lipid-lowering therapy with RSV/EZT was associated with a greater decrease in low-density lipoprotein cholesterol levels compared with RSV (75.87+31.64 vs 87.19 + 31.7, p=004), while no differential effect on triglyceride, high-density lipoprotein cholesterol or high-sensitivity C-reactive protein levels was noted between groups. At 12 months, a similar decrease in estimated glomerular filtration rate (eGFR) was noted. Patients that achieved an LDL-C <100 mg/dL had less eGFR decrease compared with patients above this LDL-C limit. There were no significant changes in the urinary total protein to creatinine ratio in either group. Significant microalbuminuria was evident in both groups.Conclusion: These findings indicate that statin therapy intensified by ezetimibe may reduce the incidence of cardiovascular events within the first 12 months after vascular surgery. Patients undergoing vascular surgery show a deterioration of renal function during the first year, despite statin therapy. Intensified lipid lowering therapy by adding EZT does not appear to have any renoprotective effect. Nonetheless, the use of ezetimibe as an add-on therapy to reduce cardiovascular risk in these patients needs to be tested in larger future studies.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2014

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kouvelos, Georgios
  • Κούβελος, Γεώργιος

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/37377

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kouvelos, Georgios; Κούβελος, Γεώργιος. Η επίδραση της επιθετικής υπολιπιδαιμικής αγωγής σε αγγειακούς ασθενείς που υποβάλλονται σε χειρουργική θεραπεία. University of Ioannina, 2014. http://hdl.handle.net/10442/hedi/37377